Track Qilian International Holding Group Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Qilian International Holding Group Limited QLI · Stock Open Qilian International Holding Group Limited in new tab

5.41 USD
Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Qilian International Holding Group Limited (QLI)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Qilian International Holding Group Limited Logo Qilian International Holding Group Limited Analysis (QLI)

China Health Care Official Website Stock

Is Qilian International Holding Group Limited a good investment? Qilian International Holding Group Limited (QLI) is currently trading at 5.41 USD.

Investor FAQ

Does Qilian International Holding Group Limited pay a dividend?

No, it does not currently pay a dividend.

What asset class is Qilian International Holding Group Limited?

Qilian International Holding Group Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Exchange Ticker
NMS (United States) QLI
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
2023
0.05 USD
March 6, 2023 0.0500
Stock Splits
Split Date Split Ratio to 1
June 21, 2024 0.200000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion